The global genetic testing market was valued at $7,501.90 million in 2017 and is projected to reach $17,606.70 million by 2025, growing at a CAGR of 11.3% from 2018 to 2025.
Genetic testing is the study of DNA that identifies gene mutation associated with a variety of genetic disorder. There are various types of genetic testing, and several methods such as cytogenetic testing, biochemical testing, molecular testing, molecular testing, and chromosome analysis are used to determine the changes in persons chromosomes, genes, or proteins. The outcomes of a genetic test confirm or diagnose a suspected genetic condition or help determine a persons chance of developing or passing on a genetic disorder.
The global genetic testing market is expected to register substantial growth in the near future, owing to rise in incidence of genetic disorders & cancer and growth in awareness & acceptance of personalized medicines. In addition, advancements in genetic testing techniques are expected to boost the market growth during the forecast period. However, standardization concerns of genetic testing-based diagnostics and stringent regulatory requirements for product approvals are anticipated to hamper the market growth during the forecast period. Conversely, untapped emerging markets in developing countries are expected to provide remunerative opportunities for the market players.
The global genetic testing market is segmented based on type, technology, application, and region. By type, the market is categorized into predictive testing, predictive testing, prenatal & newborn testing, diagnostic testing, pharmacogenomic testing, and others. On the basis of technology, the market is divided into cytogenetic testing, molecular testing, and DNA sequencing. By application, it is segmented into cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. Region wise, the market analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global genetic testing market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
By Type
o Predictive Testing
o Carrier Testing
o Prenatal & Newborn Testing
o Diagnostic Testing
o Pharmacogenomic Testing
o Others
By Technology
o Cytogenetic Testing/Chromosome Analysis
o Biochemical Testing
o Molecular Testing
DNA Sequencing
Others
By Application
o Chromosome Analysis
o Genetic Disease Diagnosis
o Cardiovascular Disease Diagnosis
o Others
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Australia
Japan
India
China
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
KEY MARKET PLAYERS
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Myriad Genetics, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Eurofins Scientific
Illumina, Inc.
Qiagen N.V.
Novartis International AG
Thermo Fisher Scientific, Inc.
The other players in the value chain include (profiles not included in the report):
Agilent Technologies, Inc.
Empire Genomics, LLC.
Irvine Scientific
PerkinElmer, Inc.
Sysmex Corporation
Chapter: 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
Chapter: 2: EXECUTIVE SUMMARY
2.1. CXO perspective
Chapter: 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porters five forces analysis
3.4. Top Player Positioning, 2017
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in incidence of genetic disorders & cancer
3.5.1.2. Rise in awareness & acceptance of personalized medicines
3.5.1.3. Advancements in genetic testing techniques
3.5.2. Restraint
3.5.2.1. Standardization concerns of genetic testing-based diagnostics
3.5.2.2. Stringent regulatory requirements for product approvals
3.5.3. Opportunities
3.5.3.1. Untapped emerging markets in developing countries
3.6. Patent analysis (2015-2018)
3.6.1. Patent analysis, by year
3.6.2. Patent analysis for year 2017, by country
Chapter: 4: GENETIC TESTING MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Predictive and presymptomatic testing
4.2.1. Key trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Carrier testing
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Prenatal and newborn testing
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Diagnostic testing
4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
4.6. Pharmacogenomic testing
4.6.1. Key trends and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
4.7. Others
4.7.1. Key trends and opportunities
4.7.2. Market size and forecast
4.7.3. Market analysis, by country
Chapter: 5: GENETIC TESTING MARKET, BY TECHNOLOGY
5.1. Overview
5.1.1. Market size and forecast
5.2. Cytogenetic testing/chromosome analysis
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Biochemical testing
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Molecular testing
5.4.1. Market size and forecast, by type
5.4.2. DNA Sequencing
5.4.2.1. Market size and forecast, by region
5.4.3. Others
5.4.3.1. Market size and forecast, by region
5.4.4. Market size and forecast
5.4.5. Market analysis, by country
Chapter: 6: GENETIC TESTING MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Cancer diagnosis
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Genetic disease diagnosis
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Cardiovascular disease diagnosis
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
6.5. Others
6.5.1. Market size and forecast
6.5.2. Market analysis, by country
Chapter: 7: GENETIC TESTING MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by test type
7.2.3. Market size and forecast, by technology
7.2.4. Market size and forecast, by application
7.2.5. Market size and forecast, by country
7.2.5.1. U.S. market size and forecast, by test type
7.2.5.2. U.S. market size and forecast, by technology
7.2.5.3. U.S. market size and forecast, by application
7.2.5.4. Canada market size and forecast, by test type
7.2.5.5. Canada market size and forecast, by technology
7.2.5.6. Canada market size and forecast, by application
7.2.5.7. Mexico market size and forecast, by test type
7.2.5.8. Mexico market size and forecast, by technology
7.2.5.9. Mexico market size and forecast, by application
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by test type
7.3.3. Market size and forecast, by technology
7.3.4. Market size and forecast, by application
7.3.5. Market size and forecast, by country
7.3.5.1. Germany market size and forecast, by test type
7.3.5.2. Germany market size and forecast, by technology
7.3.5.3. Germany market size and forecast, by application
7.3.5.4. France market size and forecast, by test type
7.3.5.5. France market size and forecast, by technology
7.3.5.6. France market size and forecast, by application
7.3.5.7. UK market size and forecast, by test type
7.3.5.8. UK market size and forecast, by technology
7.3.5.9. UK market size and forecast, by application
7.3.5.10. Italy market size and forecast, by test type
7.3.5.11. Italy market size and forecast, by technology
7.3.5.12. Italy market size and forecast, by application
7.3.5.13. Spain market size and forecast, by test type
7.3.5.14. Spain market size and forecast, by technology
7.3.5.15. Spain market size and forecast, by application
7.3.5.16. rest of Europe market size and forecast, by test type
7.3.5.17. rest of Europe market size and forecast, by technology
7.3.5.18. Rest of Europe market size and forecast, by application
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by test type
7.4.3. Market size and forecast, by technology
7.4.4. Market size and forecast, by application
7.4.5. Market size and forecast, by country
7.4.5.1. Japan market size and forecast, by test type
7.4.5.2. Japan market size and forecast, by technology
7.4.5.3. Japan market size and forecast, by application
7.4.5.4. China market size and forecast, by test type
7.4.5.5. China market size and forecast, by technology
7.4.5.6. China market size and forecast, by application
7.4.5.7. Australia market size and forecast, by test type
7.4.5.8. Australia market size and forecast, by technology
7.4.5.9. Australia market size and forecast, by application
7.4.5.10. India market size and forecast, by test type
7.4.5.11. India market size and forecast, by technology
7.4.5.12. India market size and forecast, by application
7.4.5.13. South Korea market size and forecast, by test type
7.4.5.14. South Korea market size and forecast, by technology
7.4.5.15. South Korea market size and forecast, by application
7.4.5.16. Rest of Asia-Pacific market size and forecast, by test type
7.4.5.17. Rest of Asia-Pacific market size and forecast, by technology
7.4.5.18. Rest of Asia-Pacific market size and forecast, by application
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by test type
7.5.3. Market size and forecast, by technology
7.5.4. Market size and forecast, by application
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil market size and forecast, by test type
7.5.5.2. Brazil market size and forecast, by technology
7.5.5.3. Brazil market size and forecast, by application
7.5.5.4. Saudi Arabia market size and forecast, by test type
7.5.5.5. Saudi Arabia market size and forecast, by technology
7.5.5.6. Saudi Arabia market size and forecast, by application
7.5.5.7. South Africa market size and forecast, by test type
7.5.5.8. South Africa market size and forecast, by technology
7.5.5.9. South Africa market size and forecast, by application
7.5.5.10. Rest of LAMEA market size and forecast, by test type
7.5.5.11. Rest of LAMEA market size and forecast, by technology
7.5.5.12. Rest of LAMEA market size and forecast, by application
Chapter: 8: COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. BIO-RAD LABORATORIES, INC. (RAINDANCE TECHNOLOGIES, INC.)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. DANAHER CORPORATION (CEPHEID)
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. EUROFINS SCIENTIFIC
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Product portfolio
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. F. HOFFMANN-LA ROCHE LTD.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. ILLUMINA, INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. MYRIAD GENETICS, INC. (MYRIAD RBM, INC.)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. NOVARTIS INTERNATIONAL AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. QIAGEN N.V. (FORMULATRIX, INC.)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product portfolio
8.9.4. Business performance
8.9.5. Key strategic moves and developments
8.10. THERMO FISHER SCIENTIFIC, INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance